HRP20010884A2 - Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists - Google Patents

Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists Download PDF

Info

Publication number
HRP20010884A2
HRP20010884A2 HR20010884A HRP20010884A HRP20010884A2 HR P20010884 A2 HRP20010884 A2 HR P20010884A2 HR 20010884 A HR20010884 A HR 20010884A HR P20010884 A HRP20010884 A HR P20010884A HR P20010884 A2 HRP20010884 A2 HR P20010884A2
Authority
HR
Croatia
Prior art keywords
citrate
monohydrate
anhydrous
crystalline
polymorph
Prior art date
Application number
HR20010884A
Other languages
English (en)
Croatian (hr)
Inventor
Stephen Sargent Massett
George Joseph Quallich
Peter Robert Rose
Lewin Theophilus Wint
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HRP20010884A2 publication Critical patent/HRP20010884A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20010884A 1999-06-01 2001-11-27 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists HRP20010884A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13699599P 1999-06-01 1999-06-01
PCT/IB2000/000663 WO2000073303A1 (en) 1999-06-01 2000-05-17 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20010884A2 true HRP20010884A2 (en) 2003-04-30

Family

ID=22475353

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010884A HRP20010884A2 (en) 1999-06-01 2001-11-27 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists

Country Status (38)

Country Link
US (1) US6387925B1 (ko)
EP (1) EP1181289A1 (ko)
JP (1) JP2003501353A (ko)
KR (1) KR20020005055A (ko)
CN (1) CN1353712A (ko)
AP (1) AP2001002350A0 (ko)
AR (1) AR029753A1 (ko)
AU (1) AU767331B2 (ko)
BG (1) BG106139A (ko)
BR (1) BR0011125A (ko)
CA (1) CA2372236A1 (ko)
CO (1) CO5170468A1 (ko)
CR (1) CR6513A (ko)
CZ (1) CZ20014270A3 (ko)
DZ (1) DZ3051A1 (ko)
EA (1) EA004206B1 (ko)
EE (1) EE200100655A (ko)
GT (1) GT200000086A (ko)
HK (1) HK1046407A1 (ko)
HN (1) HN2000000076A (ko)
HR (1) HRP20010884A2 (ko)
HU (1) HUP0201798A3 (ko)
IL (1) IL145952A0 (ko)
IS (1) IS6129A (ko)
MX (1) MXPA01012328A (ko)
NO (1) NO20015845L (ko)
NZ (1) NZ514762A (ko)
OA (1) OA11955A (ko)
PA (1) PA8496001A1 (ko)
PE (1) PE20010155A1 (ko)
PL (1) PL352715A1 (ko)
SK (1) SK17342001A3 (ko)
SV (1) SV2002000092A (ko)
TN (1) TNSN00119A1 (ko)
TR (1) TR200103472T2 (ko)
UY (1) UY26177A1 (ko)
WO (1) WO2000073303A1 (ko)
ZA (1) ZA200109839B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503859A (ja) * 2002-10-04 2006-02-02 メルク シャープ エンド ドーム リミテッド 受容体拮抗薬としてのアザ二環式スピロエーテル誘導体
PT1638937E (pt) * 2003-06-18 2009-01-27 Teva Pharma Forma xiv cristalina de fluvastatina sódica, processos para a sua preparação, composições que a contêm e métodos de utilização
US7371906B2 (en) 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
RU2103269C1 (ru) * 1991-05-31 1998-01-27 Пфайзер Инк. Производные хинуклидина или их фармацевтически приемлемые соли и фармацевтическая композиция
KR950704311A (ko) * 1992-11-12 1995-11-17 알렌 제이. 스피겔 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist)
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

Also Published As

Publication number Publication date
NZ514762A (en) 2002-12-20
CN1353712A (zh) 2002-06-12
AU767331B2 (en) 2003-11-06
CR6513A (es) 2003-11-25
TR200103472T2 (tr) 2002-05-21
CA2372236A1 (en) 2000-12-07
NO20015845L (no) 2002-01-30
CO5170468A1 (es) 2002-06-27
IS6129A (is) 2001-10-26
JP2003501353A (ja) 2003-01-14
EA004206B1 (ru) 2004-02-26
PE20010155A1 (es) 2001-02-08
SV2002000092A (es) 2002-02-05
KR20020005055A (ko) 2002-01-16
HUP0201798A3 (en) 2002-10-28
AR029753A1 (es) 2003-07-16
IL145952A0 (en) 2002-07-25
DZ3051A1 (fr) 2004-03-27
TNSN00119A1 (fr) 2005-11-10
SK17342001A3 (sk) 2002-10-08
BR0011125A (pt) 2002-02-19
MXPA01012328A (es) 2002-07-30
PA8496001A1 (es) 2002-07-30
AP2001002350A0 (en) 2001-12-31
OA11955A (en) 2006-04-13
WO2000073303A1 (en) 2000-12-07
US6387925B1 (en) 2002-05-14
EA200100982A1 (ru) 2002-06-27
EE200100655A (et) 2003-02-17
HUP0201798A2 (en) 2002-09-28
BG106139A (bg) 2002-05-31
AU4424600A (en) 2000-12-18
PL352715A1 (en) 2003-09-08
EP1181289A1 (en) 2002-02-27
HK1046407A1 (zh) 2003-01-10
HN2000000076A (es) 2001-02-02
GT200000086A (es) 2001-11-21
ZA200109839B (en) 2003-01-29
UY26177A1 (es) 2000-12-29
CZ20014270A3 (cs) 2002-08-14
NO20015845D0 (no) 2001-11-30

Similar Documents

Publication Publication Date Title
DD297640A5 (de) Verfahren zur herstellung anellierter tetrahydropyridinessigsaeurederivate
HRP20010884A2 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists
HRP20010920A2 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists
HRP20010904A2 (en) Polymorphs of a crystalline azabicyclo[2,2,2]octan-3-amine citrate and their pharmaceutical compositions
SK15032000A3 (sk) Maleínan paroxetínu, spôsob jeho výroby a jeho použitie
CA3108134A1 (en) Crystalline eltrombopag monoethanolamine salt form d
US20220227769A1 (en) Crystalline form of telmapitant or (5r,8s)-8-[[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione
AU2007227919B2 (en) Pharmaceutical composition containing clopidogrel camphorsulfonate or polymorphic forms thereof
US4113877A (en) Substituted 2-aminomethylphenyl sulfamates
WO1999061441A1 (en) Polymorphs of crystalline (7s,9as)-7-[ 3-cyanophenoxy] methyl-2-(5- fluoropyrimidin-2- yl)-2,3,4,6,7,8,9a -octahydro-1h-pyrido[1,2-a] pyrazine- monohydrochloride and their pharmaceutical compositions
SI21067A2 (sl) Amlodipin hemimaleat
EA008141B1 (ru) Способ получения малеата амлодипина

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
OBST Application withdrawn